Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

NCT02613403 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases

Interventions

DRUG: MK-3682B
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC